A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: first insight of the underlying mechanisms

CONCLUSIONS: We reproductively obtained resistant organoids FoxR that significantly showed less sensitivity to FOLFORINOX treatment than the PaTa-1818x naive organoids from which they were derived. Our resistant model is representative of the sequential steps of chemoresistance observed in patients in terms of growth arrest (proliferation blockade), residual disease (cell quiescence/dormancy) and relapse.SIGNIFICANCE: To our knowledge, this is the first genuine in vitro model of resistance to the three drugs in combined therapy. This new PDO model will be a great asset for the discovery of acquired chemoresistance mechanisms, knowledge that is mandatory before offering new therapeutic strategies for pancreatic cancer. This article is protected by copyright. All rights reserved.PMID:34561874 | DOI:10.1111/boc.202100003

Source: Biology of the Cell - September 25, 2021 Category: Cytology Authors: Elsa Hadj Bachir Charles Poiraud Sonia Paget Nicolas Stoup Soumaya El Moghrabi Belinda Duch êne Nathalie Jouy Antonino Bongiovanni Meryem Tardivel Louis-Bastien Weiswald Marie Vandepeutte C ésar Beugniez Fabienne Escande Emmanuelle Leteurtre OrgaRES con Source Type: research